Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO
Splice modulation using antisense oligonucleotides (AOs) has been shown to yield targeted exon exclusion to restore the open reading frame and generate truncated but partially functional dystrophin protein. This has been successfully demonstrated in dystrophin-deficient mdx mice and in Duchenne musc...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Cell Press
2010
|
| _version_ | 1826280251081097216 |
|---|---|
| author | Yin, H Moulton, H Betts, C Merritt, T Seow, Y Ashraf, S Wang, Q Boutilier, J Wood, MJA |
| author_facet | Yin, H Moulton, H Betts, C Merritt, T Seow, Y Ashraf, S Wang, Q Boutilier, J Wood, MJA |
| author_sort | Yin, H |
| collection | OXFORD |
| description | Splice modulation using antisense oligonucleotides (AOs) has been shown to yield targeted exon exclusion to restore the open reading frame and generate truncated but partially functional dystrophin protein. This has been successfully demonstrated in dystrophin-deficient mdx mice and in Duchenne muscular dystrophy (DMD) patients. However, DMD is a systemic disease; successful therapeutic exploitation of this approach will therefore depend on effective systemic delivery of AOs to all affected tissues. We have previously shown the potential of a muscle-specific/arginine-rich chimeric peptide-phosphorodiamidate morpholino (PMO) conjugate, but its long-term activity, optimized dosing regimen, capacity for functional correction and safety profile remain to be established. Here, we report the results of this chimeric peptide-PMO conjugate in the mdx mouse using low doses (3 and 6 mg/kg) administered via a 6 biweekly systemic intravenous injection protocol. We show 100% dystrophin-positive fibers and near complete correction of the dystrophin transcript defect in all peripheral muscle groups, with restoration of 50% dystrophin protein over 12 weeks, leading to correction of the DMD pathological phenotype and restoration of muscle function in the absence of detectable toxicity or immune response. Chimeric muscle-specific/cell-penetrating peptides therefore represent highly promising agents for systemic delivery of splice-correcting PMO oligomers for DMD therapy. |
| first_indexed | 2024-03-07T00:10:53Z |
| format | Journal article |
| id | oxford-uuid:79323a01-9d5b-4217-9119-e4e2d0bad647 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:10:53Z |
| publishDate | 2010 |
| publisher | Cell Press |
| record_format | dspace |
| spelling | oxford-uuid:79323a01-9d5b-4217-9119-e4e2d0bad6472022-03-26T20:35:49ZFunctional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMOJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:79323a01-9d5b-4217-9119-e4e2d0bad647EnglishSymplectic Elements at OxfordCell Press2010Yin, HMoulton, HBetts, CMerritt, TSeow, YAshraf, SWang, QBoutilier, JWood, MJASplice modulation using antisense oligonucleotides (AOs) has been shown to yield targeted exon exclusion to restore the open reading frame and generate truncated but partially functional dystrophin protein. This has been successfully demonstrated in dystrophin-deficient mdx mice and in Duchenne muscular dystrophy (DMD) patients. However, DMD is a systemic disease; successful therapeutic exploitation of this approach will therefore depend on effective systemic delivery of AOs to all affected tissues. We have previously shown the potential of a muscle-specific/arginine-rich chimeric peptide-phosphorodiamidate morpholino (PMO) conjugate, but its long-term activity, optimized dosing regimen, capacity for functional correction and safety profile remain to be established. Here, we report the results of this chimeric peptide-PMO conjugate in the mdx mouse using low doses (3 and 6 mg/kg) administered via a 6 biweekly systemic intravenous injection protocol. We show 100% dystrophin-positive fibers and near complete correction of the dystrophin transcript defect in all peripheral muscle groups, with restoration of 50% dystrophin protein over 12 weeks, leading to correction of the DMD pathological phenotype and restoration of muscle function in the absence of detectable toxicity or immune response. Chimeric muscle-specific/cell-penetrating peptides therefore represent highly promising agents for systemic delivery of splice-correcting PMO oligomers for DMD therapy. |
| spellingShingle | Yin, H Moulton, H Betts, C Merritt, T Seow, Y Ashraf, S Wang, Q Boutilier, J Wood, MJA Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO |
| title | Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO |
| title_full | Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO |
| title_fullStr | Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO |
| title_full_unstemmed | Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO |
| title_short | Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO |
| title_sort | functional rescue of dystrophin deficient mdx mice by a chimeric peptide pmo |
| work_keys_str_mv | AT yinh functionalrescueofdystrophindeficientmdxmicebyachimericpeptidepmo AT moultonh functionalrescueofdystrophindeficientmdxmicebyachimericpeptidepmo AT bettsc functionalrescueofdystrophindeficientmdxmicebyachimericpeptidepmo AT merrittt functionalrescueofdystrophindeficientmdxmicebyachimericpeptidepmo AT seowy functionalrescueofdystrophindeficientmdxmicebyachimericpeptidepmo AT ashrafs functionalrescueofdystrophindeficientmdxmicebyachimericpeptidepmo AT wangq functionalrescueofdystrophindeficientmdxmicebyachimericpeptidepmo AT boutilierj functionalrescueofdystrophindeficientmdxmicebyachimericpeptidepmo AT woodmja functionalrescueofdystrophindeficientmdxmicebyachimericpeptidepmo |